Makoto Mori1, Syed Usman Bin Mahmood1, Asher J Schranz2, Ibrahim Sultan3, Andrea L Axtell4, Nadeen Sarsour5, William Hiesinger6, Marko T Boskovski7, Sameer Hirji7, Tsuyoshi Kaneko7, Joseph Woo6, Paul Tang5, Arminder S Jassar4, Pavan Atluri8, Bryan A Whitson9, Thomas Gleason3, Arnar Geirsson10. 1. Section of Cardiac Surgery, Yale University School of Medicine, New Haven, Conn. 2. University of North Carolina School of Medicine, Chapel Hill, NC. 3. University of Pittsburgh Medical Center, Pittsburgh, Pa. 4. Massachusetts General Hospital, Boston, Mass. 5. University of Michigan Medical School, Ann Arbor, Mich. 6. Stanford University School of Medicine, Palo Alto, Calif. 7. Brigham and Women's Hospital, Boston, Mass. 8. Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa. 9. Wexner Medical Center, The Ohio State University, Columbus, Ohio. 10. Section of Cardiac Surgery, Yale University School of Medicine, New Haven, Conn. Electronic address: arnar.geirsson@yale.edu.
Abstract
BACKGROUND: We aimed to quantify incidence and operative risks associated with reoperative valve surgeries (RVS) in patients with drug-associated infective endocarditis in a multi-center setting. METHODS: We formed a registry of patients with drug-associated infective endocarditis who underwent valve surgeries at 8 US centers between 2011 and 2017. Outcomes of first-time valve surgery (FVS) and RVS were compared. Multivariable logistic regression models related RVS to 30-day mortality. Poisson regression models were fitted to evaluate temporal trends in overall case volume and proportions of patients undergoing RVS. RESULTS: The cohort consisted of 925 patients with drug-associated infective endocarditis who underwent a valve surgery, of which 652 were FVS and 273 were RVS. Patients undergoing FVS had fewer comorbidities than those undergoing RVS. Overall case volume increased from 108 in 2012 to 229 cases in 2017 (P < .001). The proportion of redo valve cases increased from 19% in 2012 to 28% in 2017 (P < .001). The 30-day mortality in RVS was higher compared with FVS (8.1% vs 4.8%; P = .049). An increase in unadjusted mortality rates were observed as the number of prior cardiac surgeries increased, from 4.8% in FVS to 11.8% in ≥3 RVS. Multivariable model demonstrated that RVS was associated with an increased risk of 30-day mortality (odds ratio, 2.22; 95% confidence interval, 1.22-4.06; P = .010). CONCLUSIONS: An increasing proportion of valve surgery for drug-associated infective endocarditis is for RVS. Despite being young and harboring few comorbidities, the RVS cohort is still susceptible to increased risk of 30-day mortality compared with those undergoing FVS.
BACKGROUND: We aimed to quantify incidence and operative risks associated with reoperative valve surgeries (RVS) in patients with drug-associated infective endocarditis in a multi-center setting. METHODS: We formed a registry of patients with drug-associated infective endocarditis who underwent valve surgeries at 8 US centers between 2011 and 2017. Outcomes of first-time valve surgery (FVS) and RVS were compared. Multivariable logistic regression models related RVS to 30-day mortality. Poisson regression models were fitted to evaluate temporal trends in overall case volume and proportions of patients undergoing RVS. RESULTS: The cohort consisted of 925 patients with drug-associated infective endocarditis who underwent a valve surgery, of which 652 were FVS and 273 were RVS. Patients undergoing FVS had fewer comorbidities than those undergoing RVS. Overall case volume increased from 108 in 2012 to 229 cases in 2017 (P < .001). The proportion of redo valve cases increased from 19% in 2012 to 28% in 2017 (P < .001). The 30-day mortality in RVS was higher compared with FVS (8.1% vs 4.8%; P = .049). An increase in unadjusted mortality rates were observed as the number of prior cardiac surgeries increased, from 4.8% in FVS to 11.8% in ≥3 RVS. Multivariable model demonstrated that RVS was associated with an increased risk of 30-day mortality (odds ratio, 2.22; 95% confidence interval, 1.22-4.06; P = .010). CONCLUSIONS: An increasing proportion of valve surgery for drug-associated infective endocarditis is for RVS. Despite being young and harboring few comorbidities, the RVS cohort is still susceptible to increased risk of 30-day mortality compared with those undergoing FVS.
Authors: Christopher M Jones; Melinda Campopiano; Grant Baldwin; Elinore McCance-Katz Journal: Am J Public Health Date: 2015-06-11 Impact factor: 9.308
Authors: Tahaniyat Lalani; Vivian H Chu; Lawrence P Park; Enrico Cecchi; G Ralph Corey; Emanuele Durante-Mangoni; Vance G Fowler; David Gordon; Paolo Grossi; Margaret Hannan; Bruno Hoen; Patricia Muñoz; Hussien Rizk; Souha S Kanj; Christine Selton-Suty; Daniel J Sexton; Denis Spelman; Veronica Ravasio; Marie Françoise Tripodi; Andrew Wang Journal: JAMA Intern Med Date: 2013-09-09 Impact factor: 21.873
Authors: Joon Bum Kim; Julius I Ejiofor; Maroun Yammine; Masahiko Ando; Janice M Camuso; Ilan Youngster; Sandra B Nelson; Arthur Y Kim; Serguei I Melnitchouk; James D Rawn; Thomas E MacGillivray; Lawrence H Cohn; John G Byrne; Thoralf M Sundt Journal: J Thorac Cardiovasc Surg Date: 2016-03-12 Impact factor: 5.209
Authors: Andrew Wang; Eugene Athan; Paul A Pappas; Vance G Fowler; Lars Olaison; Carlos Paré; Benito Almirante; Patricia Muñoz; Marco Rizzi; Christoph Naber; Mateja Logar; Pierre Tattevin; Diana L Iarussi; Christine Selton-Suty; Sandra Braun Jones; José Casabé; Arthur Morris; G Ralph Corey; Christopher H Cabell Journal: JAMA Date: 2007-03-28 Impact factor: 56.272
Authors: Syed Usman Bin Mahmood; Max Jordan Nguemeni Tiako; Makoto Mori; John A Elefteriades; Pramod Bonde; Arnar Geirsson; James J Yun Journal: Thorac Cardiovasc Surg Date: 2018-10-08 Impact factor: 1.827
Authors: Ryan Hall; Michael Shaughnessy; Griffin Boll; Kenneth Warner; Helen W Boucher; Raveendhara R Bannuru; Alysse G Wurcel Journal: Clin Infect Dis Date: 2019-09-13 Impact factor: 9.079
Authors: Sean M O'Brien; David M Shahian; Giovanni Filardo; Victor A Ferraris; Constance K Haan; Jeffrey B Rich; Sharon-Lise T Normand; Elizabeth R DeLong; Cynthia M Shewan; Rachel S Dokholyan; Eric D Peterson; Fred H Edwards; Richard P Anderson Journal: Ann Thorac Surg Date: 2009-07 Impact factor: 4.330
Authors: Arnar Geirsson; Asher Schranz; Oliver Jawitz; Makoto Mori; Liqi Feng; Brittany A Zwischenberger; Alexander Iribarne; Joseph Dearani; Gregory Rushing; Vinay Badhwar; Juan A Crestanello Journal: Ann Thorac Surg Date: 2020-05-06 Impact factor: 4.330
Authors: Jeffrey W Cannon; J W Awori Hayanga; Thomas B Drvar; Matthew Ellison; Christopher Cook; Muhammad Salman; Harold Roberts; Vinay Badhwar; Heather K Hayanga Journal: Am J Case Rep Date: 2021-03-29